Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
暂无分享,去创建一个
B. Pégourié | O. Decaux | P. Moreau | H. Avet-Loiseau | M. Macro | X. Leleu | G. Marit | C. Mathiot | T. Facon | V. Richez | B. Arnulf | M. Attal | B. Royer | P. Rodon | J. Fermand | L. Garderet | M. Roussel | L. Karlin | A. Stoppa | M. Wetterwald | C. Hulin | D. Caillot | G. Fouquet | A. Banos | M. Petillon | B. Kolb | M. Roussel | L. Benbouker | S. Brechiniac | M. Escoffre-barbe | Sabine Brechiniac
[1] Alese E. Halvorson,et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. , 2014, Blood.
[2] D. Jayne,et al. SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .
[3] Z. Sheng,et al. Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma , 2016, Hematological oncology.
[4] K. Anderson,et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. , 2014, Blood.
[5] G. Morgan,et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma , 2014, Leukemia.
[6] R A Kyle,et al. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma , 2014, Leukemia.
[7] M. Boccadoro,et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. , 2013, Blood.
[8] P. Richardson,et al. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. , 2013, Critical reviews in oncology/hematology.
[9] H. Goldschmidt,et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.
[10] A. Dispenzieri,et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma , 2013, Blood Cancer Journal.
[11] B. Pégourié,et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. , 2013, Blood.
[12] N. Munshi,et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. , 2013, Blood.
[13] H. Goldschmidt,et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.
[14] P. L. Bergsagel,et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. , 2010, Blood.
[15] P. L. Bergsagel,et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) , 2010, Leukemia.
[16] T. Therneau,et al. Clinical course of patients with relapsed multiple myeloma. , 2004, Mayo Clinic proceedings.